Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Yoshindo Announces Shipment Curbs for Cymbalta Generics, 6 Other APIs
June 22, 2021
- Otsuka Group Takes the Lead to Launch Workplace Vaccination as Industry Peers Set to Follow
June 22, 2021
- NanoCarrier’s Angiosarcoma Med Bags US FDA’s Fast Track Designation
June 22, 2021
- Yoshindo’s Cymbalta Generics Out, but Supply Restrictions in Place: Sources
June 21, 2021
- Astellas CEO Earns 488 Million Yen in FY2020: Securities Filing
June 21, 2021
- Global Brands Clinch Targeted Sales despite COVID-19, Drive Japan Makers in FY2020
June 21, 2021
- Eisai Forms Strategic Alliance with BMS for Its First ADC
June 21, 2021
- Astellas to Write Off 21.5 Billion Yen as Peanut Allergy Vaccine Fails
June 18, 2021
- Merck’s COVID-19 Drug Candidate Enters PIII in Japan
June 18, 2021
- Zacras AG Now Available, Aloxi AG Expected for September Launch
June 18, 2021
- Kyowa Adjusting Cymbalta Generic Supply before Launch as Rivals Delay Release
June 18, 2021
- Nichi-Iko Licenses Its Remicade Biosimilar to Argentine Drug Maker
June 18, 2021
- Delays in Cymbalta Generic Launch Stir Worries on Demand Spike for 2 Makers
June 17, 2021
- Astellas Offloads 5 Legacy Products to Germany’s Cheplapharm
June 17, 2021
- Daiichi Sankyo Ships AstraZeneca COVID-19 Vaccine to Taiwan, Vietnam
June 17, 2021
- Kitasato Institute, Meiji Eye Ivermectin Derivative Use for Post-COVID-19 Symptoms Too
June 16, 2021
- Enhertu Enters PIII for 1st Line HER2-Positive Breast Cancer
June 16, 2021
- Daiichi Sankyo Drops Nafamostat Development for COVID-19
June 16, 2021
- Rohto Initiates Japan PII of Stem Cell Therapy for Severe COVID-19 Pneumonia
June 16, 2021
- Eisai to Transfer Zonegran’s European Rights to UK Firm
June 16, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…